- Home
- VIVS
as 06-06-2025 4:00pm EST
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as VivoSim Labs Inc. Common Stock VIVS prepares to release earnings report on 13 Jun 2025.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 71.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.56 - $21.96 | Next Earning Date: | 06-13-2025 |
| Revenue: | $144,000 | Revenue Growth: | -49.59% |
| Revenue Growth (this year): | 59.08% | Revenue Growth (next year): | 18.24% |
Latest VivoSim Labs Inc. Common Stock News
VIVS Breaking Stock News: Dive into VIVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
25 days ago
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference
GlobeNewswire
a month ago
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference
Compare VIVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VIVS VivoSim Labs Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.